Johnson & Johnson to separate Orthopaedics business, create Depuy Synthes

🔔 Big news from J&J! 🔔 Johnson & Johnson has announced plans to separate its Orthopedics business into an independent, publicly traded company under the well-known DePuy Synthes brand. This move allows J&J to sharpen its focus on higher-growth areas within Innovative Medicine and MedTech, such as Cardiovascular, Surgery, and Vision, while enabling the new company to become the world’s largest pure-play orthopedics firm, tapping into a global market opportunity exceeding $50B. With 2024 sales of ~$9.2B, the Orthopedics business is positioned for renewed focus and investment, under the leadership of Namal Nawana as Worldwide President. The planned separation, expected to be completed in 18–24 months, reflects a growing trend among large healthcare companies to unlock value and enhance strategic clarity through focused portfolios. A bold and potentially transformative step in the evolving MedTech landscape. #Healthcare #MedTech #CorporateStrategy #JohnsonAndJohnson #Orthopedics #DePuySynthes

Today we’re announcing our intent to separate our Orthopaedics business. We’re confident this move would further strengthen the focus of Johnson & Johnson on our six key growth areas – Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. It would also establish a standalone Orthopaedics business, operating as Depuy Synthes, that would be the largest, most comprehensive orthopaedics-focused company with leading market share positions across major product categories. Learn more: https://lnkd.in/ekMP46rg

A strategic move by Johnson & Johnson to strengthen its focus on key growth areas like Oncology, Immunology, and Neuroscience - while empowering the Orthopaedics business to innovate independently as a global leader. #Leadership #HealthcareInnovation #JJ

Johnson & Johnson delivered another strong performance in the third quarter fueled by the depth and strength of our portfolio and significant progress across our pipeline. With a sharpened focus on the six priority areas of Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision, #JNJ is in a new era of accelerated growth and innovation, with pioneering treatments that will continue to transform lives.    Hear more about our progress in my conversation with Becky Quick on CNBC:

🎀 This week’s European Radiology Journals Newsletter is live! From diffusion-weighted MRI to image-guided therapy, explore the latest in breast imaging and oncology research 👇 🧠DWI for monitoring neoadjuvant therapy response 💧 Cutting the contrast? DWI shows similar value 🏥 Preoperative breast MRI & surgical outcomes ✨ The benefits of pre-operative MRI 🚫 Withdrawing from MRI screening — out of sight, not out of risk 🎯 Image-guided adaptation of systemic therapy 👉 Read the full highlights here: https://buff.ly/3FZyw7u

I am pleased to share our recent publication in BMC Urology: “Prognostic impact of non-clear cell histology on recurrence and cancer-free survival in renal cell carcinoma: a time-to-event analysis.” This study highlights the prognostic value of tumor size, pathological stage, vascular invasion, and lymph node involvement in predicting recurrence, while showing comparable outcomes between clear cell and non-clear cell RCC. 🔗 Read the full article https://lnkd.in/dx35-fqH

Thermography is often marketed as a radiation-free alternative to mammograms. But here’s the truth: thermography is not FDA approved as a stand-alone breast cancer screening tool and can miss obvious cancers, detecting only about half of what mammography does. Major medical organizations including the Society of Breast Imaging, the American College of Radiology and The The American Society of Breast Surgeons do not recommend it as a substitute. If you’re considering thermography, use it only as an adjunct and always follow up with standard imaging like mammography, ultrasound or MRI. https://lnkd.in/gTBkPbtr #BreastCancerAwarenessMonth #BreastHealth #MammogramSavesLives #EarlyDetection #40AndEmpowered

🇺🇸💊 Johnson & Johnson Q3 2025 Earnings:   - Adj EPS $2.80 (est $2.78) - Rev $23.99B (est $23.74B) - Medtech Sales $8.43B (est $8.38B) - Medicine Rev $15.56B (est $15.38B) - Sees FY Sales $93.5B To $93.9B, Saw $93.2B To $93.6B - Still Sees FY Adj EPS $10.80 To $10.90 CEO Commentary: “We delivered another strong quarter and are sharpening focus on six priority areas-Oncology, Immunology, Neuroscience, Cardiovascular, Surgery and Vision-entering a new era of accelerated growth and innovation.” #JNJ #Report #Earnings #HealthTechnology

#UltrasoundTechnology is Ushering in a New Era of #Surgery Free #CancerTreatment What was once used only for imaging is now revolutionizing cancer care. Researchers and clinicians are using focused ultrasound to destroy tumors non invasively, offering patients a #safer, #faster, and less #painful alternative to traditional treatments like surgery, #chemotherapy, and #radiation. A groundbreaking ultrasound technique pioneered by Zhen Xu at the University of Michigan, now approved for #liverCancer treatment. Tumors are targeted with microscopic bubbles that break them apart, without damaging surrounding healthy tissue. Approved in the U.S. and the U.K., with ongoing trials expanding to other cancers such as kidney and pancreas. Ultrasound is being paired with immunotherapy, radiation, and drug delivery innovations to boost effectiveness and minimize side effects. Experts like Richard Price and #DeepaSharma highlight how this advancement could transform oncology, bringing hope to patients worldwide. This is more than just medical innovation, it’s a paradigm shift in how we approach cancer treatment. #Techmatters #CancerTreatment #MedicalInnovation #UltrasoundTherapy #Histotripsy #Oncology #HealthTech #ZhenXu #RichardPrice #DeepaSharma #UniversityOfMichigan #CancerResearch #SurgeryFreeTreatment #HealthcareInnovation #FutureOfMedicine

Robert Goldman MD, DO, PhD Worldhealth.net A genomic test predicts which prostate cancer patients benefit from #hormone therapy after surgery. Luminal B tumors respond well, while others don’t, ushering in truly personalized treatment decisions. A milestone in precision oncology. #prostatecancer #genomics #precisionmedicine #cancerresearch #hormones #medicalresearch #antiaging #regenerativemedicine #medicine #health #menshealth #wellness https://lnkd.in/gYzFDKUc